Laird Forrest

This inventor holds 7 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: University of Kansas, Hylapharm, LLC, University of Michigan. Active years: 2012-2025.

USPTO Granted Patents = 7 (Patent Applications = 2)

% Patents Active = 85.7

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 5.6

ph-index = 1

Forward Citations = 5(Granted Patents)

Location History:

Fawrence, KS (US) (2022)
Lawrence, KS (US) (2012 - 2024)

Company Filing History:

University of Michigan

patents

where one patent can have more than one assignee

Years Active: 2012-2025

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12329827 - Devices, compositions and related methods for accelerating and enhancing bone repair (2025-06-17),

2. 12295970 - Imidazoquinoline compounds and prodrugs thereof (2025-05-13),

3. 11952337 - Bioenergetically active esters for health and disease (2024-04-09),

4. 11458163 - Platinum(IV) conjugates and methods of use (2022-10-04),

5. 11332432 - Bioenergetically active esters for health and disease (2022-05-17),

6. 11045556 - Devices, compositions and related methods for accelerating and enhancing bone repair (2021-06-29),

7. 8088412 - Intralymphatic chemotherapy drug carriers (2012-01-03),

Title: Laird Forrest: Innovator in Bone Repair and Cancer Treatment

Introduction

Laird Forrest is a notable inventor based in Lawrence, KS (US), recognized for his contributions to the fields of bone repair and cancer treatment. With a total of 7 patents, he has made significant advancements through his innovative research and development.

Latest Patents

Among his latest patents, Laird Forrest has developed devices, compositions, and related methods for accelerating and enhancing bone repair. This invention focuses on novel therapeutic nanoparticles that are associated with angiogenesis-activating agents. The technology aims to enhance and activate angiogenesis at targeted tissue regions, providing new therapeutic options for patients. Another significant patent involves imidazoquinoline compounds and prodrugs, which serve as TLR7 and TLR8 agonist compounds. These compounds are designed for the treatment of cancers and as vaccine adjuvants, showcasing his commitment to addressing critical health challenges.

Career Highlights

Laird Forrest has worked with esteemed organizations such as the University of Kansas and Hylapharm, LLC. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Laird has collaborated with talented individuals, including Ti Zhang and Jordan Hunt, who have played a role in his innovative projects.

Conclusion

Laird Forrest's work exemplifies the impact of innovation in medicine, particularly in enhancing bone repair and cancer treatment. His patents reflect a dedication to improving patient outcomes through advanced therapeutic solutions.